CVE:LBL

Lattice Biologics Competitors

C$0.04

-0.01 (-10.00 %)

(As of 03/4/2021 10:59 AM ET)

Add

Compare

Today's Range

C$0.05

Now: C$0.05▼

C$0.05

50-Day Range

C$0.00

MA: C$0.07▼

C$0.13

52-Week Range

C$0.02

Now: C$0.05▼

C$0.21

Volume245,000 shs

Average Volume842,412 shs

Market CapitalizationC$5.77 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Lattice Biologics (CVE:LBL) Vs. SUGR, NU, AQS, THCX, GLH, and ACG

Should you be buying LBL stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Lattice Biologics, including SugarBud Craft Growers Corp. (SUGR.V) (SUGR), NeutriSci International (NU), Aequus Pharmaceuticals (AQS), (THCX.V) (THCX), 31444 (GLH), and 438280 (ACG).

Lattice Biologics vs. SugarBud Craft Growers Corp. (SUGR.V) Stock

Lattice Biologics (CVE:LBL) and SugarBud Craft Growers Corp. (SUGR.V) (CVE:SUGR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Lattice Biologics and SugarBud Craft Growers Corp. (SUGR.V)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lattice Biologics	N/A	N/A	N/A
SugarBud Craft Growers Corp. (SUGR.V)	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings for Lattice Biologics and SugarBud Craft Growers Corp. (SUGR.V), as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lattice Biologics	0	0	0	0	N/A
SugarBud Craft Growers Corp. (SUGR.V)	0	0	0	0	N/A

Earnings and Valuation

This table compares Lattice Biologics and SugarBud Craft Growers Corp. (SUGR.V)'s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lattice Biologics	C$2.46 million	2.34	C$-1,795,052.00	C($0.01)	-3.21
SugarBud Craft Growers Corp. (SUGR.V)	C$66,906.00	552.49	C$-473,614,575.00	C($1.03)	-0.08

Lattice Biologics has higher revenue and earnings than SugarBud Craft Growers Corp. (SUGR.V). Lattice Biologics is trading at a lower price-to-earnings ratio than SugarBud Craft Growers Corp. (SUGR.V), indicating that it is currently the more affordable of the two stocks.

Summary

Lattice Biologics beats SugarBud Craft Growers Corp. (SUGR.V) on 3 of the 5 factors compared between the two stocks.

Lattice Biologics vs. NeutriSci International Stock

Lattice Biologics (CVE:LBL) and NeutriSci International (CVE:NU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Lattice Biologics and NeutriSci International's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lattice Biologics	N/A	N/A	N/A
NeutriSci International	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings for Lattice Biologics and NeutriSci International, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lattice Biologics	0	0	0	0	N/A
NeutriSci International	0	0	0	0	N/A

Earnings and Valuation

This table compares Lattice Biologics and NeutriSci International's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lattice Biologics	C$2.46 million	2.34	C$-1,795,052.00	C($0.01)	-3.21
NeutriSci International	C$69,626.00	317.51	C$-1,982,032.00	C($0.01)	-11.15

Lattice Biologics has higher revenue and earnings than NeutriSci International. NeutriSci International is trading at a lower price-to-earnings ratio than Lattice Biologics, indicating that it is currently the more affordable of the two stocks.

Summary

Lattice Biologics beats NeutriSci International on 3 of the 5 factors compared between the two stocks.

Lattice Biologics vs. Aequus Pharmaceuticals Stock

Lattice Biologics (CVE:LBL) and Aequus Pharmaceuticals (CVE:AQS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Lattice Biologics and Aequus Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lattice Biologics	N/A	N/A	N/A
Aequus Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings for Lattice Biologics and Aequus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lattice Biologics	0	0	0	0	N/A
Aequus Pharmaceuticals	0	0	0	0	N/A

Earnings and Valuation

This table compares Lattice Biologics and Aequus Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lattice Biologics	C$2.46 million	2.34	C$-1,795,052.00	C($0.01)	-3.21
Aequus Pharmaceuticals	C$2.28 million	11.80	C$-2,462,174.00	C($0.02)	-10.91

Lattice Biologics has higher revenue and earnings than Aequus Pharmaceuticals. Aequus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lattice Biologics, indicating that it is currently the more affordable of the two stocks.

Summary

Lattice Biologics beats Aequus Pharmaceuticals on 4 of the 5 factors compared between the two stocks.

Lattice Biologics vs. (THCX.V) Stock

Lattice Biologics (CVE:LBL) and (THCX.V) (CVE:THCX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Lattice Biologics and (THCX.V)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lattice Biologics	N/A	N/A	N/A
(THCX.V)	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings for Lattice Biologics and (THCX.V), as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lattice Biologics	0	0	0	0	N/A
(THCX.V)	0	0	0	0	N/A

Earnings and Valuation

This table compares Lattice Biologics and (THCX.V)'s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lattice Biologics	C$2.46 million	2.34	C$-1,795,052.00	C($0.01)	-3.21
(THCX.V)	N/A	N/A	N/A	N/A	N/A

(THCX.V) has lower revenue, but higher earnings than Lattice Biologics.

Summary

Lattice Biologics beats (THCX.V) on 1 of the 1 factors compared between the two stocks.

Lattice Biologics vs. 31444 Stock

Lattice Biologics (CVE:LBL) and 31444 (CNSX:GLH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Lattice Biologics and 31444's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lattice Biologics	N/A	N/A	N/A
31444	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings for Lattice Biologics and 31444, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lattice Biologics	0	0	0	0	N/A
31444	0	0	0	0	N/A

Earnings and Valuation

This table compares Lattice Biologics and 31444's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lattice Biologics	C$2.46 million	2.34	$-1,795,052.00	C($0.01)	-3.21
31444	N/A	N/A	N/A	N/A	N/A

31444 has lower revenue, but higher earnings than Lattice Biologics.

Summary

Lattice Biologics beats 31444 on 1 of the 1 factors compared between the two stocks.

Lattice Biologics vs. 438280 Stock

Lattice Biologics (CVE:LBL) and 438280 (CNSX:ACG) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of current ratings for Lattice Biologics and 438280, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lattice Biologics	0	0	0	0	N/A
438280	0	0	0	0	N/A

Profitability

This table compares Lattice Biologics and 438280's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lattice Biologics	N/A	N/A	N/A
438280	N/A	N/A	N/A

Earnings and Valuation

This table compares Lattice Biologics and 438280's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lattice Biologics	C$2.46 million	2.34	C$-1,795,052.00	C($0.01)	-3.21
438280	N/A	N/A	N/A	N/A	N/A

438280 has lower revenue, but higher earnings than Lattice Biologics.

Summary

Lattice Biologics beats 438280 on 1 of the 1 factors compared between the two stocks.